Cagrilintide Product Brief

Ready-to-Sell Research Product Sheet

1. Compound Overview

Cagrilintide is a long-acting amylin analog that has been investigated for its potential role in metabolic regulation and appetite signaling pathways.
Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells and plays a role in regulating satiety, gastric emptying, and glucose metabolism.

Cagrilintide has been studied in metabolic and obesity research models for its potential influence on appetite control and energy balance.

2. Mechanism of Interest

Cagrilintide is studied for several biological mechanisms:

• Amylin receptor agonism
  • Influence on appetite regulation pathways
  • Delayed gastric emptying mechanisms
  • Potential impact on metabolic signaling pathways
  • Interaction with satiety centers in the brain

3. Research Areas Being Explored

• Appetite regulation research
  • Weight management studies
  • Metabolic signaling pathways
  • Glucose metabolism research
  • Combination metabolic therapy studies

4. Suggested Research Vial Sizes

• 5 mg lyophilized vial
  • 10 mg lyophilized vial
  • 20 mg research vial

5. Example Reconstitution Chart

Example mixing protocols commonly used in research contexts:

5 mg vial + 1 mL bacteriostatic water = 5 mg/mL concentration

10 mg vial + 2 mL bacteriostatic water = 5 mg/mL concentration

20 mg vial + 4 mL bacteriostatic water = 5 mg/mL concentration

These concentrations allow accurate measurement using insulin syringes for laboratory research settings.

6. Label Information for Vials

• Compound name: Cagrilintide
  • Total amount per vial (mg)
  • Lot / batch number
  • Manufacturing date
  • Storage instructions (2–8°C recommended)
  • Research use only disclaimer

7. Market Positioning

Cagrilintide is commonly positioned in the metabolic research peptide category.

It is frequently associated with research exploring:

• Appetite regulation
  • Metabolic signaling pathways
  • Weight management research models
  • Combination metabolic peptide studies

8. Example Research Stack Categories

• Cagrilintide + Semaglutide
  • Cagrilintide + Tirzepatide
  • Cagrilintide + AOD-9604
  • Cagrilintide + 5-Amino-1MQ

9. Safety and Regulatory Notes

Cagrilintide is not approved by the FDA as a standalone treatment and is commonly distributed in research settings for laboratory study.

This document is intended for informational and research product description purposes only.